ZINC-BASED DIAGNOSTIC FOR PROSTATE CANCER

基于锌的前列腺癌诊断

• 批准号: 6486502
• 负责人: CHRISTOPHER J. FREDERICKSON
• 金额: $ 16.82万
• 依托单位: NEUROBIOTEX, INC.
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-01 至 2004-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6486502
• 关键词: clinical chemistry; clinical research; diagnosis design /evaluation; human tissue; male; method development; neoplasm /cancer diagnosis; prostate neoplasms; semen; zinc

DESCRIPTION(provided by applicant): We shall develop analytical tools for measuring the amount and speciation of zinc in semen; these tools will facilitate basic research and may lead to a zinc-based diagnostic kit for prostate cancer. According to the prevailing literature, semen zinc falls by 50 percent-90 percent in the early stages of prostate cancer while not changing in benign hypertrophy. If this is true, a combined measurement of semen zinc (falling in cancer) and serum PSA (rising in cancer) could provide sensitive and selective early diagnosis for prostate cancer. We envision test kits for routine testing of seminal zinc in the clinic, or even at home. Our Phase I goals are (i) develop methods and materials for measuring all the different seminal zinc pools (free, microligand-bound, protein bound, spermatozoan), (ii) establish preliminary norms for the various zinc pools in control men and (iii) measure the same parameters in samples from select prostate cancer patients. If Phase I results warrant continuation, in Phase II we will (i) prototype procedures for home/office kits for testing semen zinc, (ii) gather large-sample clinical data on zinc as a screening tool for prostate cancer (iii) develop quantitative models of the best multi-zinc pool diagnostic of cancer. PROPOSED COMMERCIAL APPLICATION: Commercial Potential: Yearly PSA testing is recommended for all men over 50, yet 40,000 men still die annually in the US alone from prostate cancer. If a zinc-based test were used along with PSA testing, the sales of the tests could be vast, and the contribution to men's health and wellness, equally vast.

描述(由申请人提供)：我们将开发分析工具 测量精液中锌的含量和形态；这些工具将 促进基础研究，并可能导致基于锌的诊断试剂盒 前列腺癌。 根据流行的文献，精液锌会下降50%-90% 前列腺癌早期的百分比，而良性前列腺癌的百分比没有变化 肥大。如果这是真的，精液锌的联合测量(下降到 癌症)和血清PSA(癌症中升高)可提供敏感性和选择性 前列腺癌的早期诊断。我们设想用于常规测试的测试工具包 在临床上，甚至在家里的精锌。 我们的第一阶段目标是(I)开发方法和材料来测量所有 不同的精锌库(游离、微量配基结合、蛋白质结合、 精子)，(2)建立各种锌库的初步标准 对照人员和(Iii)在选择的样本中测量相同的参数 前列腺癌患者。 如果第一阶段的结果需要继续，我们将在第二阶段：(I)原型 家庭/办公室精液锌检测试剂盒程序，(Ii)收集 锌作为前列腺癌筛查工具的大样本临床数据 (3)建立最佳多锌矿藏诊断的定量模型 癌症。 建议的商业应用： 商业潜力：建议所有50岁以上的男性每年进行PSA检测，但仅在美国，每年仍有4万男性死于前列腺癌。如果以锌为基础的测试与PSA测试一起使用，这些测试的销量可能会很大，对男性健康和健康的贡献也同样巨大。